Europe Onychomycosis Market Size & Outlook, 2023-2030
Europe onychomycosis market, 2018-2030 (US$M)
Related Markets
Europe onychomycosis market highlights
- The Europe onychomycosis market generated a revenue of USD 926.4 million in 2023.
- The market is expected to grow at a CAGR of 4.6% from 2024 to 2030.
- In terms of segment, topical was the largest revenue generating treatment in 2023.
- Topical is the most lucrative treatment segment registering the fastest growth during the forecast period.
- Country-wise, Italy is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 926.4 million |
| Market revenue in 2030 | USD 1,267.7 million |
| Growth rate | 4.6% (CAGR from 2023 to 2030) |
| Largest segment | Topical |
| Fastest growing segment | Topical |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oral, Topical |
| Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.3% of the global onychomycosis market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,201.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Onychomycosis Market Scope
Onychomycosis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe onychomycosis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 57.65% in 2023. Horizon Databook has segmented the Europe onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2018 to 2030.
The growing geriatric population is one of the key factors anticipated to lead to an increase in the prevalence of onychomycosis in Europe. As per Blueberry Therapeutics, a key provider of onychomycosis drugs and therapeutics, the prevalence of onychomycosis is high at about 23% in Europe.
Moreover, the region has several developing and developed countries like the UK, Germany, and France, which is expected to support market expansion across the region. The increasing number of market players involved in manufacturing, developing, and distributing onychomycosis drugs & therapeutics in European countries is anticipated to boost the market.
Some of the companies focusing on the onychomycosis market in the region include NovaBiotics Ltd., Blueberry Therapeutics, Almirall S.A., Moberg Pharma AB, Erchonia Corporation, and Allderma AB. Thus, the presence of major companies undertaking development activities such as clinical trials, product approvals, and partnerships for onychomycosis drugs & therapeutics is expected to boost the regional market.
Reasons to subscribe to Europe onychomycosis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe onychomycosis market databook
-
Our clientele includes a mix of onychomycosis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe onychomycosis market , including forecasts for subscribers. This continent databook contains high-level insights into Europe onychomycosis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe onychomycosis market size, by country, 2018-2030 (US$M)
Europe Onychomycosis Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
